dupilumab

dupilumab Suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354 +1-00000000000
Email: marketing@targetmol.com
Products Intro: Product Name:Dupilumab;SAR-231893;REGN-668
CAS:1190264-60-8
Purity:98.00% Package:100 mg;500 mg Remarks:REAGENT;FOR LABORATORY USE ONLY
Company Name: Wuhan Jingkang en Biomedical Technology Co., Ltd
Tel: +8613720134139
Email: orders@jknbiochem.com
Products Intro: Product Name:dupilumab
CAS:1190264-60-8
Purity:0.98 Package:10G:100G
Company Name: Shanghai Lollane Biological Technology Co.,Ltd.  
Tel: 021-52996696,15000506266 15000506266
Email:
Products Intro: Product Name:Dupilumab
Purity:98% HPLC Package:5mg,10mg,50mg,100mg,1g,5g
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Products Intro: Product Name:Dupilumab
CAS:1190264-60-8
Purity:>95% Package:10mg
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 17754423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:dupilumab
CAS:1190264-60-8
Purity:95% Package:100ug;500ug;1mg
dupilumab Basic information
Product Name:dupilumab
Synonyms:dupilumab;REGN-668;SAR-231893;Research Grade Dupilumab(DHD62601);Dupliumab
CAS:1190264-60-8
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
dupilumab Structure
dupilumab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
dupilumab Usage And Synthesis
UsesDupilumab, also known as Dupixent?, is a treatment for severe atopic eczema.
Mechanism of actionBiologics work by blocking ILs from binding to their cell receptors (protein molecules that receive chemical signals from outside a cell); this stops the immune system from overreacting. Dupilumab works on two specific ILs thought to contribute to atopic conditions: IL-4 and IL-13. By blocking IL-4 and IL-13 from binding to their cell receptors, dupilumab limits the overreaction of the immune system, dampening down the chronic inflammatory response and lessening the symptoms of atopic eczema.
PharmacokineticsDupilumab shows a non-linear rate in regard to the target.Dupilumab is also reported to have a bioavailability of 64%, with the average concentration occurring one week after in one week after injection.
Side effectsThe most common side effects reported by the US Food and Drug Administration (FDA) include injection site reactions, upper respiratory tract infections, joint pain, and herpes viral infections.The most common side effects reported by the European Medicines Agency (EMA) include injection-site reactions (such as redness, swelling including due to fluid build-up, itching and pain), conjunctivitis (redness and discomfort in the eye) including conjunctivitis due to allergy, joint pain, cold sores, and increased blood levels of a type of white blood cell called eosinophils.
dupilumab Preparation Products And Raw materials
Tag:dupilumab(1190264-60-8) Related Product Information
Lebrikizumab Etokima Tralokinumab Ustekinumab Simtuzumab Vedolizumab TocilizuMab mepolizumab Clazakizumab Ieramilimab